Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abvc Biopharma (ABVC) EBT Margin (2016 - 2025)

Historic EBT Margin for Abvc Biopharma (ABVC) over the last 13 years, with Q3 2025 value amounting to 161.69%.

  • Abvc Biopharma's EBT Margin fell 365700.0% to 161.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 1231.0%, marking a year-over-year decrease of 2309700.0%. This contributed to the annual value of 1053.71% for FY2024, which is 42109000.0% up from last year.
  • As of Q3 2025, Abvc Biopharma's EBT Margin stood at 161.69%, which was down 365700.0% from 1784.37% recorded in Q2 2025.
  • Over the past 5 years, Abvc Biopharma's EBT Margin peaked at 1784.37% during Q2 2025, and registered a low of 242959.92% during Q1 2024.
  • Over the past 5 years, Abvc Biopharma's median EBT Margin value was 1479.07% (recorded in 2023), while the average stood at 21472.59%.
  • As far as peak fluctuations go, Abvc Biopharma's EBT Margin tumbled by 2000000000bps in 2024, and later soared by 2000000000bps in 2025.
  • Quarter analysis of 5 years shows Abvc Biopharma's EBT Margin stood at 1496.5% in 2021, then tumbled by -140bps to 600.69% in 2022, then tumbled by -3937bps to 24249.38% in 2023, then plummeted by -67bps to 40515.11% in 2024, then soared by 100bps to 161.69% in 2025.
  • Its last three reported values are 161.69% in Q3 2025, 1784.37% for Q2 2025, and 401.85% during Q1 2025.